Chemotherapy-induced neuropathic pain

Current Opinion in Supportive and Palliative Care

Volumn 5, Issue 1, 2011, Pages 1-7

  Farquhar Smith, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bortezomib; Cancer pain; Neuropathy; Survivorship

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; PYRAZINE DERIVATIVE; THALIDOMIDE;

ARTICLE; CHEMICALLY INDUCED DISORDER; HUMAN; NEURALGIA; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; NEURALGIA; PYRAZINES; THALIDOMIDE;

EID: 79954565716     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328342f9cc     Document Type: Article

References (68)

1. Burton AW, Fanciullo GJ, Beasley RD, Fisch MJ. Chronic pain in the cancer survivor: a new frontier. Pain Med 2007; 8:189-198.
2. Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 2010; 14:E22-E28. One of the few sources of information of the effect of CIPN on the activities of daily living and quality of life of patients.
3. Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain 2009; 10:1146-1150.
4. Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997; 6:225-236. (Pubitemid 27293869)
5. Postma TJ, Heimans JJ, Muller MJ, et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998; 9:739-744. (Pubitemid 28394160)
6. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 2004; 12:619-625. (Pubitemid 39280311)
7. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxelinduced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006; 122:245-257. (Pubitemid 43729476)
8. Kingery WS, Guo TZ, Poree LR, Maze M. Colchicine treatment of the sciatic nerve reduces neurogenic extravasation, but does not affect nociceptive thresholds or collateral sprouting in neuropathic or normal rats. Pain 1998; 74:11-20. (Pubitemid 28097724)
9. Scuteri A, Galimberti A, Maggioni D, et al. Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology 2009; 30:312-319.
10. Ji RR, Gereau RW, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev 2009; 60:135-148. This article is a review concerning the role of MAP kinases in pain states and gives insight as to why this might be important in other neuropathic pains such as CIPN.
11. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002; 99:14374-14379. (Pubitemid 35257679)
12. Joseph EK, Levine JD. Caspase signalling in neuropathic and inflammatory pain in the rat. Eur J Neurosci 2004; 20:2896-2902. (Pubitemid 40007283)
13. Jin HW, Flatters SJ, Xiao WH, et al. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 2008; 210:229-237.
14. Alessandri-Haber N, Dina OA, Yeh JJ, et al. Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat. J Neurosci 2004; 24:4444-4452. (Pubitemid 38608155)
15. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristineinduced painful peripheral neuropathy. Pain 2004; 109:150-161. (Pubitemid 38479781)
16. Siau C, Bennett GJ. Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 2006; 102:1485-1490.
17. Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience 2007; 144:714-720. (Pubitemid 44856756)
18. Ling B, Coudore F, Decalonne L, et al. Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection. Neuropharmacology 2008; 55:724-728.
19. Ledeboer A, Jekich BM, Sloane EM, et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun 2007; 21:686-698. (Pubitemid 46829773)
20. Cata JP, Weng HR, Dougherty PM. Cyclooxygenase inhibitors and thalidomide ameliorate vincristine-induced hyperalgesia in rats. Cancer Chemother Pharmacol 2004; 54:391-397. (Pubitemid 39462963)
21. Flatters SJ, Xiao WH, Bennett GJ. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett 2006; 397:219-223.
22. Xiao WH, Bennett GJ. Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain 2008; 135:262-270. (Pubitemid 351330186)
23. Vera G, Chiarlone A, Cabezos PA, et al. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 2007; 81:468-479. (Pubitemid 47175976)
24. Rahn EJ, Zvonok AM, Thakur GA, et al. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 2008; 327:584-591.
25. Nieto FR, Entrena JM, Cendan CM, et al. Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Pain 2008; 137:520-531. (Pubitemid 351970170)
26. Thibault K, Elisabeth B, Sophie D, et al. Antinociceptive and antiallodynic effects of oral PL37, a complete inhibitor of enkephalin- catabolizing enzymes, in a rat model of peripheral neuropathic pain induced by vincristine. Eur J Pharmacol 2008; 600:71-77.
27. Bujalska M, Makulska-Nowak H. Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model. Neuro Endocrinol Lett 2009; 30:144-152.
28. Carozzi VA, Chiorazzi A, Canta A, et al. Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res 2010; 17:380-391.
29. Landowski TH, Megli CJ, Nullmeyer KD, et al. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005; 65:3828-3836. (Pubitemid 40616363)
30. Xiao W, Naso L, Bennett GJ. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med 2008; 9:505-517.
31. Cata JP, Weng HR, Lee BN, et al. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006; 72:151-169.
32. Anand P. Neurotrophic factors and their receptors in human sensory neuropathies. Prog Brain Res 2004; 146:477-492. (Pubitemid 37541400)
33. Cavaletti G, Pezzoni G, Pisano C, et al. Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neurosci Lett 2002; 322:103-106. (Pubitemid 34212031)
34. Dickenson AH. The neurobiology of chronic pain states. Anaesth Intensive Care Med 2008; 9:8-12.
35. Velasco R, Bruna J. Chemotherapy-induced peripheral neuropathy: an unresolved issue. Neurologia 2010; 25:116-131. A comprehensive and current literature review of CIPN including the most up-to-date developments, including more recent biological therapies such as bortezomib.
36. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002; 249:9-17. (Pubitemid 34119018)
37. Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003; 13:741-748. (Pubitemid 38235217)
38. Forsyth PA,Balmaceda C, Peterson K, et al. Prospective study of paclitaxelinduced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997; 35:47-53. (Pubitemid 27361845)
39. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13:27-46. (Pubitemid 351393018)
40. Stubblefield MD, Slovin S, Gregor-Cortelli B, et al. An electrodiagnostic evaluation of the effect of preexisting peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clin Oncol (R Coll Radiol) 2006; 18:410-418.
41. Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007; 8:296-306. (Pubitemid 46551871)
42. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113-3120. (Pubitemid 46638949)
43. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009; 144:895-903.
44. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27:3518-3525.
45. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116:679-686.
46. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28:2259-2266.
47. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood 2010. [Epub ahead of print]
48. Farquhar-Smith WP, Yen J, West S, Sohanpal I. Peripheral neuropathy in patients receiving bortezomib for myeloma: an audit [abstract]. In: Program and Abstracts of the IASP Annual Scientific Meeting Abstracts; 31 August 2010; Montreal, Canada.
49. El-Cheikh J, Stoppa AM, Bouabdallah R, et al. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clin Lymphoma Myeloma 2008; 8:146-152.
50. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110:1042-1049. (Pubitemid 47312870)
51. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010; 95:311-319.
52. Velasco R, Petit J, Clapes V, et al. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 2010; 15:17-25. A discussion of one strategy to reduce the incidence of BIPN. By close neurological monitoring, development of BIPN is recognized promptly and doses can be adjusted before more severe nerve damage occurs.
53. Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov 2006; 1:397-403.
54. Corso A, Mangiacavalli S, Varettoni M, et al. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res 2010; 34:471-474.
55. Chaudhry V, Cornblath DR, Polydefkis M, et al. Characteristics of bortezomiband thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008; 13:275-282.
56. Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002; 119:1020-1026. (Pubitemid 35430479)
57. Wolf S, Barton D, Kottschade L, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008; 44:1507-1515.
58. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005; 64:26-31. (Pubitemid 40082932)
59. Tsavaris N, Kopterides P, Kosmas C, et al. Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med 2008; 9:1209-1216.
60. Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007; 110:2110-2118. (Pubitemid 350036873)
61. Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res 2010; 30:2927-2933.
62. Kautio AL, Haanpaa M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008; 35:31-39. (Pubitemid 350299098)
63. Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 2002; 98:195-203. (Pubitemid 34722482)
64. Ozdogan M, Samur M, Bozcuk H, et al. Venlafaxine for treatment of chemotherapy-induced neuropathic pain. Turk J Cancer 2004; 34:110-113.
65. Rao RD, Flynn PJ, Sloan JA, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2008; 112:2802-2808. (Pubitemid 351969227)
66. Storey DJ, Colvin LA, Mackean MJ, et al. Reversal of dose-limiting carboplatininduced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery. J Pain Symptom Manage 2010; 39:e2-e4.
67. Colvin LA, Johnson PR, Mitchell R, et al. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. J Clin Oncol 2008; 26:4519-4520.
68. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85:S3-S14.